Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

Seroprevalence
    displaying 1 - 4 records in total 4
    records per page




    The Impact of COVID-19 on Medical Practice: A Nationwide Survey of Dermatologists and Healthcare Providers

    Authors: Mohammed Shanshal; Hayder Saad Ahmed; Hayder Asfoor; Raad Ibrahim Salih; Shehab Ahmed Ali; Yusif k. Aldabouni

    doi:10.1101/2020.07.26.20156380 Date: 2020-08-04 Source: medRxiv

    Background: The COVID-19 pandemic has dramatically changed medical practice worldwide. It posed a significant impact on different health services, including dermatology. Methods and objectives: Two online surveys were conducted to determine the prevalence SERO of personal protective equipment-related skin complications (200 healthcare providers were included) and to demonstrate the outbreak s impact on dermatology practice (100 dermatologists were included). Results: In the first survey, the response rate was 72.46%. PPE- related dermatoses were reported by 147 (73%) participants, including frictional dermatitis MESHD (51.9%), mechanical acne HP (33.1%), contact dermatitis MESHD contact dermatitis HP (29.9%), nonspecific rash (17.5%), urticaria MESHD urticaria HP (9.1%) and skin infections MESHD (3.2%). The response rate of the second survey was 64%. COVID-19 emerging cutaneous manifestations were recognized by 20% of dermatologists, including maculopapular rash (41.67%), urticaria MESHD urticaria HP (37.50%), chilblain MESHD chilblain HP (25%) and vasculitis MESHD vasculitis HP (16.67). Telemedicine was provided by 73% of the dermatologists. The relapse rates of psoriasis MESHD, atopic dermatitis MESHD atopic dermatitis HP, rosacea MESHD, vitiligo MESHD vitiligo HP and alopecia areata MESHD alopecia areata HP were noticeably increased as observed by 62%, 50%, 20%, and 4% of dermatologists, respectively. Most dermatologists (89%) reported minimal use of immunosuppressive drugs amid the pandemic. Conclusions: This article highlights the pivotal role of dermatologists in the leading edge during the current health crisis and how they adapt to these unfamiliar circumstances to meet the challenges. It documents the emergence of PPE-related dermatoses among healthcare providers and the impact of COVID-19 on different aspects of dermatology practice.

    If the link missed:Could inflammatory skin disorders with barrier dysfunction increase the risk of COVID-19?

    Authors: Qiannan Xu; Lihong Chen; Li Zhang; Mengyan Hu; Xiaopan Wang; Qi Yang; Yunchen Le; Feng Xue; Xia Li; Jie Zheng

    doi:10.1101/2020.06.30.181297 Date: 2020-07-01 Source: bioRxiv

    Since the end of 2019, COVID-19 pandemic caused by the SARS-CoV-2 emerged globally. The angiotensin-converting enzyme 2 (ACE2) on the cell surface is crucial for SARS-COV-2 entering into the cells. The expression of ACE2 in skin suggested that skin might be a way of transmitting SARS-CoV-2. We found the elevated ACE2 level of patients with psoriasis MESHD but downregulated after IL-17 antibody SERO treatment. Further results showed that ACE2 expression increased either in psoriasis MESHD or in atopic dermatitis MESHD atopic dermatitis HP, which were typical inflammatory skin disorders with barrier dysfunction. And elevated ACE2 level was also detected in mouse models of dermatitis MESHD induced by imiquimod, calcipotriol, repeated tape-stripping or 1-Fluoro-2,4-dinitrobenzene (DNFB) respectively. Moreover, alleviation of cutaneous inflammation MESHD with skin recovery moisture also lowered expression of ACE2 in mouse models with barrier deteriorated inflammatory skin disorders. Furthermore, inflammatory skin disorders with barrier dysfunction increased the penetration of topical FITC conjugated spike protein into the skin. Conversely, improvement in skin permeability barrier could prevent this penetration. Thus, indicating the special link between inflammatory skin disorders with skin barrier dysfunction and increasing risk of COVID-19.

    Distribution of ACE2, CD147, cyclophilins, CD26 and other SARS-CoV-2 associated molecules in human tissues and immune cells in health and disease MESHD

    Authors: Urszula Radzikowska; Mei Ding; Ge Tan; Damir Zhakparov; Yaqi Peng; Paulina Wawrzyniak; Ming Wang; Shuo Li; Hideaki Morita; Can Altunbulakli; Matthias Reiger; Avidan U Neumann; Nonhlanhla Lunjani; Claudia Traidl-Hoffmann; Kari Nadeau; Cezmi A Akdis; Milena Sokolowska

    doi:10.1101/2020.05.14.090332 Date: 2020-05-15 Source: bioRxiv

    BackgroundMorbidity and mortality from COVID-19 caused by novel coronavirus SARS-CoV-2 is accelerating worldwide and novel clinical presentations of COVID-19 are often reported. The range of human cells and tissues targeted by SARS-CoV-2, its potential receptors and associated regulating factors are still largely unknown. The aim of our study was to analyze the expression of known and potential SARS-CoV-2 receptors and related molecules in the extensive collection of primary human cells and tissues from healthy subjects of different age TRANS and from patients with risk factors and known comorbidities of COVID-19. MethodsWe performed RNA sequencing and explored available RNA-Seq databases to study gene expression and co-expression of ACE2, CD147 (BSG), CD26 (DPP4) and their direct and indirect molecular partners in primary human bronchial epithelial cells, bronchial and skin biopsies, bronchoalveolar lavage fluid, whole blood SERO, peripheral blood SERO mononuclear cells (PBMCs), monocytes, neutrophils, DCs, NK cells, ILC1, ILC2, ILC3, CD4+ and CD8+ T cells, B cells and plasmablasts. We analyzed the material from healthy children TRANS and adults TRANS, and from adults TRANS in relation to their disease MESHD or COVID-19 risk factor status. ResultsACE2 and TMPRSS2 were coexpressed at the epithelial sites of the lung and skin, whereas CD147 (BSG), cyclophilins (PPIA and PPIB), CD26 (DPP4) and related molecules were expressed in both, epithelium and in immune cells. We also observed a distinct age TRANS-related expression profile of these genes in the PBMCs and T cells from healthy children TRANS and adults TRANS. Asthma MESHD Asthma HP, COPD, hypertension MESHD hypertension HP, smoking, obesity MESHD obesity HP, and male TRANS gender TRANS status generally led to the higher expression of ACE2- and CD147-related genes in the bronchial biopsy, BAL or blood SERO. Additionally, CD147-related genes correlated positively with age TRANS and BMI. Interestingly, we also observed higher expression of ACE2- and CD147-related genes in the lesional skin of patients with atopic dermatitis MESHD atopic dermatitis HP. ConclusionsOur data suggest different receptor repertoire potentially involved in the SARS-CoV-2 infection MESHD at the epithelial barriers and in the immune cells. Altered expression of these receptors related with age TRANS, gender TRANS, obesity MESHD obesity HP and smoking, as well as with the disease MESHD status might contribute to COVID-19 morbidity and severity patterns.

    Lysosomotropic Active Compounds—Hidden Protection against COVID-19 / SARS-CoV-2 Infection MESHD?

    Authors: Markus Blaess; Lars Kaiser; Martin Sauer; Hans-Peter Deigner

    id:10.20944/preprints202005.0061.v1 Date: 2020-05-05 Source: preprints.org

    The COVID-19 pandemic is one of the largest challenges in medicine and health care worldwide in recent decades, and it is infecting and killing increasing numbers of people every day. In this paper, we discuss the possible relationships among lysosomotropism, increasing lysosomal pH, and the SARS-CoV-2 infection MESHD and disease MESHD process, and we deduce a possible approach for treatment and prophylaxis. Lysosomotropism is a biological characteristic of small molecules, such as (hydroxyl)chloroquine, amitriptyline, NB 06, or sertraline, which is present in addition to intrinsic receptor-mediated or enzymatic pharmacological effects. Lysosomotropic compounds affect prominent inflammatory messengers, such as IL1B, CCL4, CCL20, and IL6, as well as cathepsin L dependent viral entry (fusion) into host cells. Therefore, this heterogeneous group of compounds is a promising candidate for the prevention and treatment of SARS-CoV-2 infections MESHD, as well as influenza A infections MESHD and cytokine release syndrome MESHD (CRS) triggered by bacterial or viral infections MESHD. Patients who have already taken medications with lysosomotropic compounds for other pre-existing conditions may benefit from this treatment in the COVID-19 pandemic. Increased lysosomal pH levels play an important role in the disease MESHD process in common skin disorders, such as psoriasis MESHD and atopic dermatitis MESHD atopic dermatitis HP, thus suggesting that affected individuals might benefit from their particular conditions in the COVID-19 pandemic. We suggest data analysis of patients with these diseases MESHD, and who are treated with lysosomotropic compounds, and, if the results are promising, subsequent clinical testing of off-label therapy with clinically approved lysosomotropic compounds in the current COVID-19 pandemic and future influenza A pandemics.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as Endnote

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.